Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial

BACKGROUND: Carboplatin and paclitaxel administered every 3 weeks is standard-of-care first-line chemotherapy for epithelial ovarian cancer. The Japanese JGOG3016 trial showed a significant improvement in progression-free and overall survival with dose-dense weekly paclitaxel and 3-weekly carboplati...

Descripción completa

Detalles Bibliográficos
Autores principales: Clamp, Andrew R, James, Elizabeth C, McNeish, Iain A, Dean, Andrew, Kim, Jae-Weon, O'Donnell, Dearbhaile M, Hook, Jane, Coyle, Christopher, Blagden, Sarah, Brenton, James D, Naik, Raj, Perren, Tim, Sundar, Sudha, Cook, Adrian D, Gopalakrishnan, Gosala S, Gabra, Hani, Lord, Rosemary, Dark, Graham, Earl, Helena M, Hall, Marcia, Banerjee, Susana, Glasspool, Rosalind M, Jones, Rachel, Williams, Sarah, Swart, Ann Marie, Stenning, Sally, Parmar, Mahesh, Kaplan, Richard, Ledermann, Jonathan A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902268/
https://www.ncbi.nlm.nih.gov/pubmed/31791688
http://dx.doi.org/10.1016/S0140-6736(19)32259-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902268/
https://www.ncbi.nlm.nih.gov/pubmed/31791688
http://dx.doi.org/10.1016/S0140-6736(19)32259-7

Ejemplares similares